A Bio-techne brand based in Silicon Valley, ACD’s products and Pharma Assay Services are based on its proprietary RNAscope® technology, the first multiplex fluorescent and chromogenic in situ hybridization platform, capable of detecting and quantifying single molecules of RNA in situ. ACD has two product lines, namely RNAscope® and BaseScope™ consisting of assay reagent kits and 15,000+ off-the-shelf probes in addition to a Pharma Assay Services business which allow customers to run assays for their unique targets rapidly. Since its first launch in 2011, the technology boasts 1500+ citations, a new publication each day now, for single, duplex and multiplex RNA analysis.

The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to 2-3 weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.

Through ACD’s Pharma Assay Services, tissue sectioning, ISH staining, high resolution full slide scanning, scoring, and image analysis are performed by a dedicated team of highly trained specialists, scientists, and board-certified pathologists. With direct access to the developers of the technology, PAS provides unparalleled expertise in ACD’s ISH platforms and delivers fast, high quality data designed to meet your study objectives and timelines.

Media

---